Membranous nephropathy: From models to man

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2307-2314

  Beck Jr , Laurence H ^a   Salant, David J ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALPHA ENOLASE; AUTOANTIBODY; COMPLEMENT FIXING ANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; GLYCOSYLPHOSPHATIDYLINOSITOL; HLA DQA1 ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MANGANESE SUPEROXIDE DISMUTASE; UROKINASE RECEPTOR;

ALLOIMMUNIZATION; ANTIGEN ANTIBODY COMPLEX; CELL DEDIFFERENTIATION; COMPLEMENT ACTIVATION; CONFORMATIONAL TRANSITION; DIAGNOSTIC VALUE; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS CAPILLARY; HEPATITIS; HEYMANN NEPHRITIS; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOHISTOLOGY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REVIEW; STAINING; TRANSCYTOSIS;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; DISEASE MODELS, ANIMAL; GENETIC ASSOCIATION STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; RECEPTORS, PHOSPHOLIPASE A2; RECURRENCE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84902171318     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72270     Document Type: Review

References (90)

1. Polanco N, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139-274.
3. Border WA, Ward HJ, Kamil ES, Cohen AH. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest. 1982;69(2):451-461.
4. Schmiedeke TM, Stöckl FW, Weber R, Sugisaki Y, Batsford SR, Vogt A. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med. 1989;169(6):1879-1894.
5. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int. 1990;37(2):663-676.
6. Fujigaki Y, Nagase M, Honda N. Intraglomerular basement membrane translocation of immune complex (IC) in the development of passive in situ IC nephritis of rats. Am J Pathol. 1993;142(3):831-842.
7. Couser WG, Steinmuller DR, Stilmant MM, Salant DJ, Lowenstein LM. Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest. 1978;62(6):1275-1287.
8. Van Damme BJ, Fleuren GJ, Bakker WW, Vernier RL, Hoedemaeker PJ. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest. 1978;38(4):502-510.
9. Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP [editorial]. J Am Soc Nephrol. 1995;6(1):35-47.
10. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A. 1982;79(18):5557-5561.
11. Kerjaschki D, Farquhar MG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med. 1983;157(2):667-686.
12. Schiller B, He C, Salant DJ, Lim A, Alexander JJ, Quigg RJ. Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis. J Exp Med. 1998;188(7):1353-1358.
13. Shankland SJ, et al. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int. 1997;52(2):404-413.
14. Takano T, Elimam H, Cybulsky AV. Complementmediated cellular injury. Semin Nephrol. 2013;33(6):586-601.
15. Meyer-Schwesinger C, et al. A new role for the neuronal ubiquitin C-terminal hydrolase-L1 (UCH-L1) in podocyte process formation and podocyte injury in human glomerulopathies. J Pathol. 2009;217(3):452-464.
16. Kitzler TM, Papillon J, Guillemette J, Wing SS, Cybulsky AV. Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells. Biochim Biophys Acta. 2012;1823(5):1007-1016.
17. Meyer-Schwesinger C, et al. Ubiquitin C-terminal hydrolase-l1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy. Am J Pathol. 2011;178(5):2044-2057.
18. Hartleben B, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010;120(4):1084-1096.
19. Shah P, Tramontano A, Makker SP. Intramolecular epitope spreading in Heymann nephritis. J Am Soc Nephrol. 2007;18(12):3060-3066.
20. Makker SP, Kanalas JJ. Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy. J Immunol. 1989;142(10):3406-3410.
21. Debiec H, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346(26):2053-2060.
22. Debiec H, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet. 2004;364(9441):1252- 1259.
23. Debiec H, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011;364(22):2101-2110.
24. Beck LH Jr, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21.
25. Ancian P, Lambeau G, Mattei MG, Lazdunski M. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem. 1995;270(15):8963-8970.
26. Zvaritch E, Lambeau G, Lazdunski M. Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2. J Biol Chem. 1996;271(1):250-257.
27. Llorca O. Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci. 2008;65(9):1302-1310.
28. Nyström J, Fierlbeck W, Granqvist A, Kulak SC, Ballermann BJ. A human glomerular SAGE transcriptome database. BMC Nephrol. 2009;10:13.
29. Lindenmeyer MT, et al. Systematic analysis of a novel human renal glomerulus-enriched gene expression dataset. PLoS One. 2010;5(7):e11545.
30. Ju W, et al. Defining cell-type specificity at the transcriptional level in human disease. Genome Res. 2013;23(11):1862-1873.
31. Boerries M, et al. Molecular fingerprinting of the podocyte reveals novel gene and protein regulatory networks. Kidney Int. 2013;83(6):1052-1064.
32. Beck S, et al. Upregulation of group IB secreted phospholipase A (2) and its M-type receptor in rat ANTI-THY-1 glomerulonephritis. Kidney Int. 2006;70(7):1251-1260.
33. Augert A, Payre C, de Launoit Y, Gil J, Lambeau G, Bernard D. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep. 2009;10(3):271-277.
34. Vindrieux D, et al. PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res. 2013;73(20):6334-6345.
35. Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol Chem. 2004;285(2):103-136.
36. Tesar DB, Cheung EJ, Bjorkman PJ. The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells. Mol Biol Cell. 2008;19(4):1587-1593.
37. Hofstra JM, Wetzels JF. Anti-PLA (2) R antibodies in membranous nephropathy: ready for routine clinical practice? Neth J Med. 2012;70(3):109-113.
38. Schlumberger W, et al. Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1. Autoimmun Rev. 2014;13(2):108-113.
39. Hoxha E, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797-804.
40. Hoxha E, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26(8):2526-2532.
41. Qin W, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011;22(6):1137-1143.
42. Hofstra JM, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1735-1743.
43. Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One. 2013;8(4):e62151.
44. Kanigicherla D, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(5):940-948.
45. Svobodova B, Honsova E, Ronco P, Tesar V, Debiec H. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant. 2013;28(7):1839-1844.
46. Beck LH Jr, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-1550.
47. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286-1291.
48. Debiec H, et al. Autoantibodies specific for the phospholipase A2 receptor in recurrent and De Novo membranous nephropathy. Am J Transplant. 2011;11(10):2144-2152.
49. Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med. 2010;363(5):496-498.
50. Debiec H, et al. Recurrent membranous nephropathy in an allograft caused by IgG3? targeting the PLA2 receptor. J Am Soc Nephrol. 2012;23(12):1949-1954.
51. Blosser CD, Ayalon R, Nair R, Thomas C, Beck LH Jr. Very early recurrence of anti-Phospholipase A2 receptor-positive membranous nephropathy after transplantation. Am J Transplant. 2012;12(6):1637-1642.
52. Behnert A, et al. An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor. PLoS One. 2013;8(4):e61669.
53. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689-690.
54. Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol. 2013;26(5):709-715.
55. Knehtl M, et al. A case of phospholipase A receptorpositive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am J Kidney Dis. 2011;57(1):140-143.
56. Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis. 2013;62(5):1012-1017.
57. Alexander MP, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int. 2013;83(3):455-462.
58. Cravedi P, et al. Salant DJ, Benigni A, et al. Membranous nephropathy associated with IgG4-related disease. Am J Kidney Dis. 2011;58(2):272-275.
59. Fervenza FC, Downer G, Beck LH Jr, Sethi S. IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am J Kidney Dis. 2011;58(2):320-324.
60. Li XL, et al. IgG4-related membranous nephropathy with high blood low urine IgG4/IgG ratio: a case report review of the literature. Clin Rheumatol. 2014;33(1):145-148.
61. Khosroshahi A, Ayalon R, Beck LH Jr, Salant DJ, Bloch DB, Stone JH. IgG4-related disease is not associated with antibody to the phospholipase A2 receptor. Int J Rheumatol. 2012;2012:139409.
62. Liu YH, et al. Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan. J Biomed Sci. 2010;17(1):81.
63. Kim S, et al. Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract. 2010;117(3):c253-c258.
64. Stanescu HC, et al. Risk HLA-DQA1 and PLA (2) R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011;364(7):616-626.
65. Coenen MJ, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol. 2013;24(4):677-683.
66. Salant DJ. Genetic variants in membranous nephropathy: perhaps a perfect storm rather than a straightforward conformeropathy? J Am Soc Nephrol. 2013;24(4):525-528.
67. Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68(1):302-310.
68. Lv J, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol. 2013;24(8):1323-1329.
69. Murtas C, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(9):1394-1400.
70. Prunotto M, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010;21(3):507-519.
71. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest. 1980;66(6):1339- 1350.
72. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol. 1989;135(1):185-194.
73. Cybulsky AV, Rennke HG, Feintzeig ID, Salant DJ. Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest. 1986;77(4):1096-1107.
74. Huang CC, et al. IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol. 2013;26(6):799-805.
75. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med. 1995;1(3):237-243.
76. Ma H, Beck LH, Salant DJ. Membranous nephropathy-associated anti-phospholipase A2 receptor IgG4 autoantibodies activate the lectin complement pathway [abstract]. J Am Soc Nephrol. 2011;22:62A.
77. Klooster R, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain. 2012;135(pt 4):1081-1101.
78. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39(4):469-477.
79. van der Neut Kolfschoten M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554-1557.
80. Dabade TS, Grande JP, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study. Am J Transplant. 2008;8(6):1318-1322.
81. Rodriguez EF, et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am J Transplant. 2012;12(4):1029-1038.
82. El-Zoghby ZM, Grande JP, Fraile MG, Norby SM, Fervenza FC, Cosio FG. Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant. 2009;9(12):2800-2807.
83. Sprangers B, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010;5(5):790-797.
84. Barbour SJ, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81(2):190-195.
85. Lionaki S, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43-51.
86. Waldman M, Austin HA. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol. 2012;23(10):1617-1630.
87. Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013;9(8):443-458.
88. Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol. 2005;16(5):1214- 1222.
89. Nitschke L. Suppressing the antibody response with Siglec ligands. N Engl J Med. 2013;369(14):1373-1374.
90. Cybulsky AV, Quigg RJ Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol. 2005;289(4):F660-F671.